These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24320756)

  • 1. Deposition of non-spherical particles in bifurcating airways.
    Bunchatheeravate P; Curtis JS
    Pharm Dev Technol; 2014 Dec; 19(8):942-51. PubMed ID: 24320756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of particle size on regional lung deposition--what evidence is there?
    Carvalho TC; Peters JI; Williams RO
    Int J Pharm; 2011 Mar; 406(1-2):1-10. PubMed ID: 21232585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance deposition assessment in obstructed pulmonary system through numerical characterization of airflow and inhaled particles attributes.
    Lalas A; Nousias S; Kikidis D; Lalos A; Arvanitis G; Sougles C; Moustakas K; Votis K; Verbanck S; Usmani O; Tzovaras D
    BMC Med Inform Decis Mak; 2017 Dec; 17(Suppl 3):173. PubMed ID: 29297393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation strategy and use of excipients in pulmonary drug delivery.
    Pilcer G; Amighi K
    Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical perspectives on pulmonary systemic and macromolecular delivery.
    Scheuch G; Kohlhaeufl MJ; Brand P; Siekmeier R
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):996-1008. PubMed ID: 16996638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model of the deposition of aerosol particles in the respiratory tract of the rat. II. Hygroscopic particle deposition.
    Ferron GA; Upadhyay S; Zimmermann R; Karg E
    J Aerosol Med Pulm Drug Deliv; 2013 Apr; 26(2):101-19. PubMed ID: 23550602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary targeting of nanoparticle drug matrices.
    Dandekar P; Venkataraman C; Mehra A
    J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23(6):343-53. PubMed ID: 20455773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting the deposition of inhaled porous drug particles.
    Musante CJ; Schroeter JD; Rosati JA; Crowder TM; Hickey AJ; Martonen TB
    J Pharm Sci; 2002 Jul; 91(7):1590-600. PubMed ID: 12115821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Airflow, transport and regional deposition of aerosol particles during chronic bronchitis of human central airways.
    Farkhadnia F; Gorji TB; Gorji-Bandpy M
    Australas Phys Eng Sci Med; 2016 Mar; 39(1):43-58. PubMed ID: 26541595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Particle transport onto human airway surfaces.
    Heyder J
    Eur J Respir Dis Suppl; 1982; 119():29-50. PubMed ID: 6954086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Numerical simulations of particle behaviour in a realistic human airway model with varying inhalation patterns.
    Kadota K; Inoue N; Matsunaga Y; Takemiya T; Kubo K; Imano H; Uchiyama H; Tozuka Y
    J Pharm Pharmacol; 2020 Jan; 72(1):17-28. PubMed ID: 31713883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Particle engineering techniques for inhaled biopharmaceuticals.
    Shoyele SA; Cawthorne S
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1009-29. PubMed ID: 17005293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inertial deposition of particles in human branching airways.
    Johnston JR; Isles KD; Muir DC
    Inhaled Part; 1975 Sep; 4 Pt 1():61-73. PubMed ID: 1236174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals.
    Nahar K; Gupta N; Gauvin R; Absar S; Patel B; Gupta V; Khademhosseini A; Ahsan F
    Eur J Pharm Sci; 2013 Aug; 49(5):805-18. PubMed ID: 23797056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive models for deposition of inhaled diesel exhaust particles in humans and laboratory species.
    Yu CP; Xu GB
    Res Rep Health Eff Inst; 1987; (10):3-22. PubMed ID: 2478161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approaches to enhance pulmonary delivery of proteins and peptides.
    Scheuch G; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):615-25. PubMed ID: 18204175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.
    Rogueda PG; Traini D
    Expert Opin Drug Deliv; 2007 Nov; 4(6):595-606. PubMed ID: 17970663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment methods of inhaled aerosols: technical aspects and applications.
    Jaafar-Maalej C; Andrieu V; Elaissari A; Fessi H
    Expert Opin Drug Deliv; 2009 Sep; 6(9):941-59. PubMed ID: 19637979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Pulmonary Cell Culture in Pharmaceutical Inhalation Aerosol Delivery: 2-D, 3-D, and In Situ Bioimpactor Models.
    Acosta MF; Muralidharan P; Meenach SA; Hayes D; M-Black S; Mansour HM
    Curr Pharm Des; 2016; 22(17):2522-31. PubMed ID: 26831643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A theoretical approach to the deposition and clearance of fibers with variable size in the human respiratory tract.
    Sturm R; Hofmann W
    J Hazard Mater; 2009 Oct; 170(1):210-8. PubMed ID: 19477590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.